Applied Therapeutics (APLT)
(Real Time Quote from BATS)
$6.13 USD
-0.01 (-0.16%)
Updated Aug 28, 2024 01:20 PM ET
3-Hold of 5 3
F Value B Growth A Momentum D VGM
Applied Therapeutics Inc. (APLT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$11.40 | $14.00 | $7.00 | 85.67% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for Applied Therapeutics Inc. comes to $11.40. The forecasts range from a low of $7.00 to a high of $14.00. The average price target represents an increase of 85.67% from the last closing price of $6.14.
Analyst Price Targets (5 )
Broker Rating
Applied Therapeutics Inc. currently has an average brokerage recommendation (ABR) of 1.17 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.17 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, five are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 83.33% and 16.67% of all recommendations. A month ago, Strong Buy made up 83.33%, while Buy represented 16.67%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/APLT.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 4 | 4 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.17 | 1.17 | 1.17 | 1.20 | 1.20 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/7/2024 | SVB Securities | Joseph P Schwartz | Strong Buy | Strong Buy |
7/31/2024 | William Blair | Timothy F Lugo | Not Available | Strong Buy |
7/17/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
3/6/2024 | UBS | Colin N Bristow | Not Available | Strong Buy |
3/5/2024 | Robert W. Baird & Co. | Brian P Skorney | Strong Buy | Strong Buy |
2/16/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.17 |
ABR (Last week) | 1.17 |
# of Recs in ABR | 6 |
Average Target Price | $11.40 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 83 of 253 |
Current Quarter EPS Est: | -0.13 |